<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593668</url>
  </required_header>
  <id_info>
    <org_study_id>MET2018</org_study_id>
    <nct_id>NCT03593668</nct_id>
  </id_info>
  <brief_title>Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control</brief_title>
  <official_title>Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control :A Randomized, Open, Controlled and Single-site Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open, controlled and single-site clinical trail to investigate the
      effect and safety of Benaglutide or Metformin in patients with simple obesity who have
      inadequate weight control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open, controlled and single-site clinical trail to investigate the
      effect and safety of Benaglutide or Metformin in patients with simple obesity who have
      inadequate weight control.

      Screening will be made to select eligible participants before intervention. Patients were
      randomly assigned to one of two groups(metformin or benaglutide) for therapies for 12 weeks
      including a two-week dose adjustment period and a 10-week dose stabilization period.
      Lifestyle interventions will be maintained during the treatment period. Subjects are followed
      up every 4 weeks for examinations.At the end of the study, data will be collected and
      analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>Change from Baseline after 12 weeks treatment</time_frame>
    <description>Changes in body weight from baseline were observed in patients with simple obesity after 12 weeks of treatment intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in body mass index (BMI) of subjects</measure>
    <time_frame>Change from Baseline after 12 weeks treatment</time_frame>
    <description>All 30 subjects of each group would be evaluted by changes in body mass index (BMI) after 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Fat Levels</measure>
    <time_frame>Change from Baseline after 12 weeks treatment</time_frame>
    <description>Changes in Body Fat Levels from Baseline: Body Composition Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood lipid levels</measure>
    <time_frame>Change from Baseline after 12 weeks treatment</time_frame>
    <description>The changes in blood lipid levels such as cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein will be measured at the beginning and the end.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity; Drug</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>2-week dose adjustment period（0-2weeks）[before meals] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.
10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Metformin Hydrochloride Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benaglutide</intervention_name>
    <description>2-week dose adjustment period（0-2weeks） [before meals] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.
10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH</description>
    <arm_group_label>Benaglutide</arm_group_label>
    <other_name>Benaglutide Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1)20 years old≤70 years old; (2) simple obesity, gender is not limited; (3)
        28.0≤BMI≤37.5kg/m2; (4) Before the screening period, the body weight was controlled by
        lifestyle interventions (diet and exercise) for at least 3 months, and weight was decreased
        by &lt;5% from baseline; (5) Agree to sign the informed consent form;

        Exclusion Criteria:

          1. Accurately diagnosed as having type 1 or type 2 diabetes according to the WHO 1999
             diagnostic criteria;

          2. Use weight loss drugs within 3 months before screening;

          3. Metformin was used within the first 3 months of screening;

          4. Malignant tumors (excluding basal cell or squamous cell carcinoma treated) within 5
             years before enrollment

          5. Alanine aminotransferase or aspartate aminotransferase &gt; 3 times the upper limit of
             normal or total serum bilirubin (TB) &gt;34.2 μmol/L (&gt;2 mg/dL)

          6. Patients with moderate/severe renal impairment or end-stage renal disease (eGFR &lt; 60
             mL/min/1.73 m2); male subjects with serum creatinine (Cr) ≥133 μmol/L (≥1.50 mg/dL
             Serum Cr in female subjects was ≥124 μmol/L (&gt;1.40 mg/dL);

          7. Severe heart, lung, nervous, mental and infectious diseases;

          8. Pregnancy, lactation and recent pregnancy plans;

          9. Alternate or chronic systemic corticosteroid therapy, defined as treatment with any
             dose of systemic corticosteroids within 3 months of enrollment visit V1 &gt; 4 weeks

         10. History of alcohol abuse, history of abuse of active drugs (opioids, analgesics, etc.)
             within 6 months before enrollment;

         11. Give any other test drug within 30 days before enrollment or within 5 half-lives of
             other test drugs;

         12. Patients with past history or family history of medullitary thyroid cancer (MTC) and
             patients with type 2 multiple endocrine tumor syndrome (MEN2);

         13. Inability to tolerate benalutide, metformin;

         14. Any influence of the investigator's judgment on enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalong Zhu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the Affiliated Drum Tower Hospital of Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dalong Zhu, MD,PhD</last_name>
    <phone>86-25-83-105302</phone>
    <email>zhudldr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Bi, MD,PhD</last_name>
    <phone>86-25-83-105302</phone>
    <email>biyan@nju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalong Zhu, MD,PhD</last_name>
      <phone>86-25-83-105302</phone>
      <email>zhudldr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yan Bi, MD,PhD</last_name>
      <phone>86-25-83-105302</phone>
      <email>biyan@nju.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Dalong Zhu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Bi, MD，PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Dalong Zhu</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Benaglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

